New hope for transplant patients with stubborn CMV infection
NCT ID NCT06577363
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 18 times
Summary
This study in Japan tracks 250 organ or stem cell transplant patients whose CMV infection hasn't cleared with standard treatments. They will take Maribavir tablets as part of their normal care, and doctors will watch for side effects and check if the virus clears from the blood over 27 weeks. The goal is to see how well the drug works and how safe it is in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.